Briana Disilvio, MD
Critical Care Medicine · Pittsburgh, PANPI 1134569973
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $186,765 of the $203,545 with a category attached, or 91.8%. 17 manufacturers reported payments, led by Boehringer Ingelheim at 57.0% of the total. 2025 is the largest year on record at $95,922, more than ten times the $564 reported in 2019. Among critical care medicine clinicians in PA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 224 payments — averaging $908.68 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boehringer Ingelheim$116K
- GSK$31K
- AstraZeneca$29K
- Verona Pharma, Inc.$26K
- Regeneron Healthcare Solutions, Inc.$253
- Pulmonx Corporation$239
- plus $985 from 11 others
Across 132 payments — averaging $1685.30 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Boehringer Ingelheim$211K
- Boehringer Ingelheim International GmbH$11K
What the payments were for
- Consulting fees$1,9501%
- Speaking & faculty fees$186,76592%
- Travel & lodging$4,6292%
- Food & beverage$9,9075%
- Education$2940%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Boehringer Ingelheim | 94 | $115,992 |
| GSK | 32 | $30,756 |
| AstraZeneca | 59 | $29,364 |
| Verona Pharma, Inc. | 18 | $25,957 |
| Regeneron Healthcare Solutions, Inc. | 4 | $253 |
| Pulmonx Corporation | 2 | $239 |
| Sanofi | 3 | $230 |
| Insmed, Inc. | 2 | $204 |
| Regeneron | 1 | $138 |
| Genentech USA, Inc. | 1 | $100 |
| Sanofi-aventis U.S. LLC | 1 | $97 |
| Boston Scientific | 1 | $56 |
| United Therapeutics Corporation | 1 | $54 |
| Teva Pharmaceuticals USA, Inc. | 2 | $38 |
| Mindray DS USA, Inc. | 1 | $30 |
| Electromed, Inc. | 1 | $27 |
| Vapotherm Inc | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- OFEV$47,452
- NUCALA$28,314
- BREZTRI$27,817
- Ohtuvayre$25,858
- FASENRA$686
- DUPIXENT$345
- TRELEGY ELLIPTA$243
- CHARTIS CATHETER$239
- ZEPHYR DELIVERY CATHETER$239
- ZEPHYR ENDOBRONCHIAL VALVE$239
- PULMONX CHARTIS TABLET CONSOLE$239
- Arikayce$129
How this compares
$203,545 in reported general payments places this provider in the 95th percentile of 354 critical care medicine providers in Pennsylvania.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OfevNintedanib Esylate | 36 | $464,463 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 113 | $78,122 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 75 | $40,785 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 54 | $39,429 |
| Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate | 83 | $13,581 |
| Breo ElliptaFluticasone/Vilanterol | 26 | $10,322 |
| DuleraMometasone/Formoterol | 23 | $7,750 |
| Spiriva RespimatTiotropium Bromide | 13 | $6,828 |
| Combivent RespimatIpratropium/Albuterol Sulfate | 14 | $6,434 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 13 | $5,717 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 38 | $5,281 |
| Fluticasone Propionate HfaFluticasone Propionate | 14 | $3,719 |
| SymbicortBudesonide/Formoterol Fumarate | 16 | $3,613 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 113 | $2,688 |
| BreynaBudesonide/Formoterol Fumarate | 11 | $2,304 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimOfev, Spiriva Respimat, Combivent Respimat, Stiolto Respimat | $115,992 | $483,44276 claims |
| GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta | $30,756 | $129,230214 claims |
| AstraZenecaBreztri Aerosphere, Symbicort | $29,364 | $43,04270 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 354 critical care medicine providers in Pennsylvania.
Other critical care medicine in Pittsburgh
- Meilin YoungPittsburgh$182K
- Kees PoldermanPittsburgh$85K
- Michael RisbanoPittsburgh$34K
- Raghavan MuruganPittsburgh$33K
- Eric BihlerPittsburgh$22K
- Tiffany DumontPittsburgh$21K
- Amy SchmetzerPittsburgh$13K
- Stephanie BaltajiPittsburgh$10K
- Billie BarkerPittsburgh$10K
- Douglas WhitePittsburgh$9K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.